



                                                                                                                                                                               
www.ghanamedj.org  Volume 52 Number 1 March 2018 1 
Hepatitis C virus infection in Ghana: time for action is now 




Chronic hepatitis C virus (HCV) infection is a blood 
borne infection just like hepatitis B virus (HBV) and 
Human Immunodeficiency Virus (HIV) with a signifi-
cant global health impact. Since the discovery of the 
HCV, several developments including a better under-
standing of the clinical epidemiology, availability of 
diagnostics and approval of newer therapies over the 
last decade have occurred and changed the frontiers of 
HCV management.  Many nations now place HCV in-
fection as a priority public health issue. In Ghana how-
ever, awareness, advocacy and treatment of HCV still 
plays a second fiddle to HBV and HIV. This must 
change and the time to act is now.  
 
The WHO estimates there has been a decline in the in 
the number of persons living with chronic HCV infec-
tions from about 130-150million to about 80million 
currently.1This decline is due partly to the fall in new 
infections since the discovery of the HCV virus in 1989.  
Ironically, deaths from HCV are on the increase.2 A 
large number of persons infected 30–60 years ago are 
now dying from HCV-related cirrhosis and hepatocellu-
lar carcinoma (HCC), as these complications often take 
decades to develop.2 This mortality trend is projected to 
continue for several more decades unless treatment is 
scaled up considerably. 
 
In Ghana, the most recent estimates of HCV infection 
from a systematic review by Agyeman et al is 3%.3 
Given that HCV transmission is highest amongst intra-
venous drug users, HIV infected individuals and homo-
sexuals and that majority of the studies in that review 
were in low risk individuals; blood donors and pregnant 
women, this is likely an underestimation. Since HCV 
infection is clinically silent in majority of carriers until 
late, the true prevalence and the burden it imposes on 
the Ghanaian health care system is likely to remain un-
known unless a comprehensive national screening poli-
cy is implemented. 
 
Blankson et al reports that 1 in14 cases of cirrhosis is 
caused by HCV in Ghana.4 Also, Yang et al, reports that 
HCC occurs at an early age in Sub-Saharan Africa in-
cluding Ghana and HCV is an important cause.5 There-
fore, it is most likely that HCV is afflicting mainly the 
workforce of Ghana. This should be a concern to all, 
and for stakeholders to commit to interventions that will 
tackle this disease. 
 
In the absence of an HCV vaccine, treatment of infected 
individuals is a major intervention to control this men-
ace. Pre-treatment evaluation includes determination of 
HCV viral load, HCV genotype and degree of liver fi-
brosis either via liver biopsy or fibroscan. These evalua-
tions are expensive and often limit the initiation of 
treatment in Ghanaians.  
 
Treatment options 
Until 2011, pegylated interferon and ribavirin for 24-72 
weeks depending on genotype and response was the 
standard of care for HCV. This treatment was complex 
with a lot of side effects and cure rates also known as 
sustained virological response (SVR) rates were poor.  
The discovery of direct acting antivirals (DAAs) from 
2011 revolutionized the treatment of HCV. Several 
combinations of DAAs provide SVR rates of more than 
90%.6 These DAAs have fewer side effects and shorter 
durations of treatment. Some DAAs are effective 
against all HCV genotypes, obviating the cost for HCV 
genotyping and simplifying treatment for clinicians. 
These medicines are however very expensive and be-
yond the means of many Ghanaians. When DAA thera-
py was introduced in the United States in 2013, the 
wholesale acquisition drug price to treat one person was 
US$ 84 000. This has since come down as a result of 
negotiated discounts, but still exceed US$ 50 000 per 
patient.6 Some governments through negotiations with 
manufactures and registration of generics have obtained 
access to these DAAs at much lower prices. This offers 
a window of opportunity to access treatment for the 
Ghanaian HCV patient. 
 
Steps have been taken in the past few years to improve 
care to the Ghanaian HCV patient. Notable amongst 
these is the publication in March 2017, of the first ever 
guidelines for the care and treatment of persons with 
hepatitis including HCV.7 
 
Several obstacles, however, remain against the success-
ful management of chronic HCV infections. Several 
infected persons are likely to remain unidentified as 
there are no defined criteria for HCV screening in Gha-
na. Voluntary testing for HCV is low because of low 
awareness. Diagnosis of chronic HCV requires both a 
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Whiles several health facilities are equipped to perform 
the screening anti-HCV antibody test, no public hospi-
tals or laboratories offer reliable HCV RNA or viral 
load and genotype testing. These have to be sourced 
from private laboratories that often send samples abroad 
at costs beyond the means of most Ghanaians. Other 
evaluations tools like the fibroscan are also lacking. 
Furthermore, only a few health care providers are well 
informed about the rapidly changing world of HCV 
infection management and so provision of treatment is 
restricted to only a few centres manned by hepatologists 
and other specialists. Access to these specialists for fur-
ther evaluation and treatment of the infected persons is a 
challenge in most parts of the country.  
 
Recommendations 
To improve the care for HCV in Ghana, the following 
strategies are recommended. 
• Improved awareness education and advocacy on 
HCV. This will encourage voluntary testing espe-
cially in the high-risk population. The national 
guidelines must also include recommendations on 
who to test for HCV. 
• Tooling of public laboratories to test for HCV RNA 
or viral load and genotype. Government investment 
will be required to procure fibroscans at least for 
the teaching hospitals to use in assessing liver fi-
brosis.  
• Capacity building of clinicians at all levels to treat 
HCV. This should be a less daunting task as DAAs 
have simplified treatment for the non-hepatologist  
• Government must negotiate with manufactures for 
reduced pricing of originator brands or actively 
promote and encourage the registration and licenc-
ing of generics.  These drugs can then be made 
available on the National Health Insurance Scheme 
(NHIS) Medicines List. 
• Encourage and fund research to gather reliable data 
on all aspects of HCV infection. This will guide 
appropriate health policies and public health deci-
sion making. 
More commitment is required from government and all 
stakeholders to meet these recommendations. Thankful-
ly, lessons from how Ghana tackled the HIV/AIDS epi-
demic are there to guide us. Time for action is now. All 
hands on deck. 
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